6.55
-0.21(-3.11%)
Currency In USD
| Previous Close | 6.76 |
| Open | 6.73 |
| Day High | 6.92 |
| Day Low | 6.41 |
| 52-Week High | 11.4 |
| 52-Week Low | 1.87 |
| Volume | 1.42M |
| Average Volume | 963,550 |
| Market Cap | 573.2M |
| PE | -6.36 |
| EPS | -1.03 |
| Moving Average 50 Days | 5.05 |
| Moving Average 200 Days | 4.56 |
| Change | -0.21 |
If you invested $1000 in Terns Pharmaceuticals, Inc. (TERN) since IPO date, it would be worth $356.17 as of August 20, 2025 at a share price of $6.55. Whereas If you bought $1000 worth of Terns Pharmaceuticals, Inc. (TERN) shares 3 years ago, it would be worth $1,633.42 as of August 20, 2025 at a share price of $6.55.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions
GlobeNewswire Inc.
Jun 23, 2025 8:07 PM GMT
Phase 1 clinical study of TERN-601 demonstrated differentiated profile in 28-day study; topline data were presented in September 2024 Phase 2 FALCON clinical trial of TERN-601 completed enrollment; 12-week data expected in 4Q 2025 FOSTER CITY, Calif.
Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences
GlobeNewswire Inc.
May 29, 2025 8:05 PM GMT
FOSTER CITY, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious d
Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701
GlobeNewswire Inc.
May 14, 2025 1:30 PM GMT
Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance mutations Early dose-escalation data from Phase 1 CARDINAL study of TERN-701 in CML patients sho